Clinical and Morphological Characteristics of Nemolizumab-Associated Cutaneous Eruptions in Atopic Dermatitis ➜ DOI: 10.1111/1346-8138.17877 This multicenter retrospective study in Japan examined 219 patients with atopic dermatitis treated with nemolizumab. The findings show that 40.2% of patients developed cutaneous manifestations, most often within the first three doses. The most common presentation was erythema, with a majority of the eruptions being non-pruritic and appearing independent of baseline disease severity or immunological markers.
Exploring Young Adults’ Self-Management of Atopic Dermatitis and Their Perceptions of Community Pharmacy Support ➜ DOI: 10.1111/hex.70378 This qualitative study of 25 young adults in the UK explored their experiences transitioning to independent atopic dermatitis (AD) self-management. The findings revealed that participants faced unique challenges, including concerns about their appearance, anxiety regarding treatment, and a limited awareness of community pharmacists as a source of health advice. The study concludes that while young adults with AD perceive a potential for pharmacists to improve access to treatment through prescribing, there is a need for practitioners and policymakers to increase awareness of the pharmacist’s role to enhance self-management.
Daily Emollient Use Reduces Atopic Dermatitis in Infants: A Community-Based Clinical Trial ➜ DOI: 10.1001/jamadermatol.2025.2357 This US randomized clinical trial, called CASCADE, found that applying emollients daily to infants from birth through 9 weeks of age significantly reduced the cumulative incidence of atopic dermatitis by 24 months in a general population not pre-selected for risk. The protective effect of the emollients was found to be strongest in infants without a family history of atopic disease and those with a dog in the household. However, as recently highlighted for similar studies, the parents who were responsible for the intervention, did not have a standardized hand hygiene protocol for emollient application.
Neonatal BCG Vaccination: A Long-Term Strategy for AD Prevention in Childhood ➜ DOI: 10.1111/all.16677 The Melbourne Infant Study (MIS BAIR), a randomized controlled trial, provides strong evidence that neonatal BCG vaccination significantly reduces the cumulative incidence of AD at 5 years of age. The study found that children who received the BCG vaccine had an 18% relative risk reduction in AD compared to the control group. However, there is a need for further research to clarify the immunological mechanisms by which the BCG vaccination confers this protection against atopic diseases.
Unlocking the Molecular Mechanisms of Atopic Dermatitis Biologics: A Structural and Thermodynamic Perspective ➜ DOI: 10.1016/j.jid.2025.06.1574 This review provides a fresh molecular perspective on biologic therapies for atopic dermatitis by analyzing the structural and thermodynamic properties of IL-4 and IL-13 signaling. It highlights that each biologic, including dupilumab, tralokinumab, lebrikizumab, and rademikibart, uniquely disrupts the assembly of the cytokine-receptor signaling complex at different energetic steps. The review explains that understanding these distinct mechanisms of action could help inform clinical decisions when a patient does not respond to a particular therapy.
